Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

20181,009 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 19, Issue 5, pp. 603-615

Field-Weighted Citation Impact: 43.40